Copyright (c) 2008 Yahoo! Inc. All rights reserved. http://news.yahoo.com/i/2168 Business - Health Care Industry en-us Tue, 19 Aug 2008 01:02:55 GMT 5 142 18 http://news.yahoo.com/i/2168 http://us.i1.yimg.com/us.yimg.com/i/us/nws/th/main_142b.gif http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080819/ap_on_el_pr/harry_louise_ads ap/20080819/harry_louise_ads AP Tue, 19 Aug 2008 01:02:55 GMT AP - Harry and Louise are back for an encore. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080818/ap_on_bi_ge/diabetes_drug_fda_warning ap/20080818/diabetes_drug_fda_warning AP Mon, 18 Aug 2008 21:24:58 GMT AP - Federal regulators are working on a stronger label for a widely used diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. as deaths continue to be reported despite earlier government warnings. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080814/ap_on_go_ca_st_pe/children_s_insurance ap/20080814/children_s_insurance AP Thu, 14 Aug 2008 22:11:05 GMT AP - The Bush administration is backing down from a threat to penalize states enrolling middle-class children in a health program intended for the poor. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/bw/20080814/bs_bw/aug2008pi20080813970347 bw/20080814/aug2008pi20080813970347 BusinessWeek Online Thu, 14 Aug 2008 12:08:45 GMT BusinessWeek Online - For managed-care organizations (MCOs), which footed the bill for roughly 34% of U.S. health care spending in 2007, health-care reform presents uncertainty and opportunity. Proposals now being debated in Washington and the different states aren't affecting near-term business, says Phillip Seligman, a Standard & Poor's equity analyst who follows MCOs. Nor are MCOs currently incorporating reform proposals into their guidance for 2008 or beyond. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ibd/20080807/bs_ibd_ibd/20080807general01 ibd/20080807/20080807general01 Investor's Business Daily Thu, 07 Aug 2008 23:02:32 GMT Investor's Business Daily - Feeding off strong demand from Big Pharma, contract medical-research firms that specialize in clinical trials keep getting healthier. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/bw/20080805/bs_bw/aug2008pi2008083973775 bw/20080805/aug2008pi2008083973775 BusinessWeek Online Tue, 05 Aug 2008 12:08:41 GMT BusinessWeek Online - Infomercial king Billy Mays, known for screaming about the wonders of cleaning solutions Kaboom!, OxiClean, and other household products, is now starring in a commercial for what he calls "the most important product I've ever endorsed:" health insurance. The bearded salesman started pitching iCan Benefit Group's "health insurance that you can actually afford" in May 2008, pointing to the need for its health plans given that 47 million Americans are uninsured. ... http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ibd/20080804/bs_ibd_ibd/20080804newamer ibd/20080804/20080804newamer Investor's Business Daily Mon, 04 Aug 2008 22:09:27 GMT Investor's Business Daily - Icon has the kind of customer demand that many businesses these days can only dream about. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080804/ap_on_bi_ge/imclone_bristol_myers_acquisition ap/20080804/imclone_bristol_myers_acquisition AP Mon, 04 Aug 2008 21:20:45 GMT <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080804/ap_on_bi_ge/imclone_bristol_myers_acquisition"><img src="http://d.yimg.com/us.yimg.com/p/nm/20080804/2008_08_04t150021_450x300_us_imclone.jpg?x=130&y=86&q=85&sig=fPlF2xRgV1ij3LJSQ7Tc1A--" align="left" height="86" width="130" alt="A laboratory researcher in a file photo. Biotechnology company ImClone Systems said on Monday that a $60-per-share takeover bid from partner Bristol-Myers Squibb Co was too low, but it would hire financial advisers to help it study the unsolicited offer. (Sebastian Derungs/Reuters)" border="0" /></a>AP - ImClone Systems Inc.'s board of directors said Monday cancer drug partner Bristol-Myers Squibb Co.'s $4.5 billion buyout offer "substantially undervalues" the company, with Chairman Carl Icahn personally against the deal.</p><br clear="all"/> <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080804/ap_on_bi_ge/imclone_bristol_myers_acquisition"><img src="http://d.yimg.com/us.yimg.com/p/nm/20080804/2008_08_04t150021_450x300_us_imclone.jpg?x=130&y=86&q=85&sig=fPlF2xRgV1ij3LJSQ7Tc1A--" align="left" height="86" width="130" alt="photo" title="A laboratory researcher in a file photo. Biotechnology company ImClone Systems said on Monday that a $60-per-share takeover bid from partner Bristol-Myers Squibb Co was too low, but it would hire financial advisers to help it study the unsolicited offer. (Sebastian Derungs/Reuters)" border="0"/></a></p><br clear="all"/> (AP) http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/nm/20080804/bs_nm/scheringplough_dc nm/20080804/scheringplough_dc Reuters Mon, 04 Aug 2008 17:44:12 GMT Reuters - Schering-Plough Corp said on Monday that results from a study of its experimental hepatitis C drug showed promising results, sending the shares of rival Vertex Pharmaceuticals Inc down nearly 11 percent. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080802/ap_on_bi_ge/prescription_drug_recall ap/20080802/prescription_drug_recall AP Sat, 02 Aug 2008 00:47:50 GMT AP - A New Jersey company is asking pharmacists and hospitals to return all prescription drug products made at one of its facilities because it did not pass health authorities' standards. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ibd/20080801/bs_ibd_ibd/20080801health ibd/20080801/20080801health Investor's Business Daily Fri, 01 Aug 2008 21:46:13 GMT Investor's Business Daily - Teva Pharmaceutical's planned buyout of Barr Pharmaceuticals for cash and stock was a headline-grabber. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080801/ap_on_bi_ge/earns_cigna ap/20080801/earns_cigna AP Fri, 01 Aug 2008 10:48:13 GMT AP - Health insurer Cigna says its second-quarter profit rose 37 percent on a jump in premiums and fees as the company's acquisition of Great West Healthcare boosted membership. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/nm/20080731/bs_nm/imclone_bristol_dc nm/20080731/imclone_bristol_dc Reuters Thu, 31 Jul 2008 23:31:56 GMT <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/nm/20080731/bs_nm/imclone_bristol_dc"><img src="http://d.yimg.com/us.yimg.com/p/nm/20080731/2008_07_31t084324_450x322_us_imclone_bristol.jpg?x=130&y=93&q=85&sig=eW2CutYv8bBVGIYsGzWeYQ--" align="left" height="93" width="130" alt="James M. Cornelius, Chief Executive Officer of Bristol-Myers Squibb, listens to questions during the Reuters Health Summit in New York November 8, 2006. (Brendan McDermid/Reuters)" border="0" /></a>Reuters - Bristol-Myers Squibb Co has offered to buy ImClone Systems Inc for $60 a share, valuing its biotech partner at $5.2 billion in a deal to strengthen its grip on the fast-growing Erbitux cancer drug.</p><br clear="all"/> <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/nm/20080731/bs_nm/imclone_bristol_dc"><img src="http://d.yimg.com/us.yimg.com/p/nm/20080731/2008_07_31t084324_450x322_us_imclone_bristol.jpg?x=130&y=93&q=85&sig=eW2CutYv8bBVGIYsGzWeYQ--" align="left" height="93" width="130" alt="photo" title="James M. Cornelius, Chief Executive Officer of Bristol-Myers Squibb, listens to questions during the Reuters Health Summit in New York November 8, 2006. (Brendan McDermid/Reuters)" border="0"/></a></p><br clear="all"/> (Reuters) http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080731/ap_on_bi_ge/bristol_myers_imclone_acquisition ap/20080731/bristol_myers_imclone_acquisition AP Thu, 31 Jul 2008 21:36:27 GMT <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080731/ap_on_bi_ge/bristol_myers_imclone_acquisition"><img src="http://d.yimg.com/us.yimg.com/p/afp/20080731/capt.cps.ndr42.310708183518.photo00.photo.default-512x336.jpg?x=130&y=85&q=85&sig=qoBx_UksF0YtC1PM.LPdMQ--" align="left" height="85" width="130" alt="A Bristol-Myers Squibb office building in Saint-Nazaire, France in 2005. Bristol-Myers Squibb, the US pharmaceuticals group, said Thursday it has offered to buy its biotechnology partner ImClone Systems in an all-cash deal worth around 4.5 billion dollars.(AFP/File/Frank Perry)" border="0" /></a>AP - Bristol-Myers Squibb Co. on Thursday offered $4.5 billion in cash for its cancer drug partner, biotechnology company ImClone Systems Inc., saying the two are "a natural fit."</p><br clear="all"/> <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080731/ap_on_bi_ge/bristol_myers_imclone_acquisition"><img src="http://d.yimg.com/us.yimg.com/p/afp/20080731/capt.cps.ndr42.310708183518.photo00.photo.default-512x336.jpg?x=130&y=85&q=85&sig=qoBx_UksF0YtC1PM.LPdMQ--" align="left" height="85" width="130" alt="photo" title="A Bristol-Myers Squibb office building in Saint-Nazaire, France in 2005. Bristol-Myers Squibb, the US pharmaceuticals group, said Thursday it has offered to buy its biotechnology partner ImClone Systems in an all-cash deal worth around 4.5 billion dollars.(AFP/File/Frank Perry)" border="0"/></a></p><br clear="all"/> (AP) http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/afp/20080731/bs_afp/uspharmacompanytakeoverbristolmyersimclone afp/20080731/uspharmacompanytakeoverbristolmyersimclone AFP Thu, 31 Jul 2008 16:37:27 GMT <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/afp/20080731/bs_afp/uspharmacompanytakeoverbristolmyersimclone"><img src="http://d.yimg.com/us.yimg.com/p/afp/20080731/capt.cps.ndr43.310708183518.photo00.photo.default-512x336.jpg?x=130&y=85&q=85&sig=C6.Zm.oblhsTofd7Rr5.jw--" align="left" height="85" width="130" alt="A Bristol-Myers Squibb office building in Saint-Nazaire, France in 2005. Bristol-Myers Squibb, the US pharmaceuticals group, said Thursday it has offered to buy its biotechnology partner ImClone Systems in an all-cash deal worth around 4.5 billion dollars.(AFP/File/Frank Perry)" border="0" /></a>AFP - Bristol-Myers Squibb, the US pharmaceuticals group, said Thursday it has offered to buy its biotechnology partner ImClone Systems in an all-cash deal worth around 4.5 billion dollars.</p><br clear="all"/> <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/afp/20080731/bs_afp/uspharmacompanytakeoverbristolmyersimclone"><img src="http://d.yimg.com/us.yimg.com/p/afp/20080731/capt.cps.ndr43.310708183518.photo00.photo.default-512x336.jpg?x=130&y=85&q=85&sig=C6.Zm.oblhsTofd7Rr5.jw--" align="left" height="85" width="130" alt="photo" title="A Bristol-Myers Squibb office building in Saint-Nazaire, France in 2005. Bristol-Myers Squibb, the US pharmaceuticals group, said Thursday it has offered to buy its biotechnology partner ImClone Systems in an all-cash deal worth around 4.5 billion dollars.(AFP/File/Frank Perry)" border="0"/></a></p><br clear="all"/> (AFP) http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/nm/20080731/bs_nm/markets_stocks_dc nm/20080731/markets_stocks_dc Reuters Thu, 31 Jul 2008 20:39:06 GMT <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/nm/20080731/bs_nm/markets_stocks_dc"><img src="http://d.yimg.com/us.yimg.com/p/nm/20080801/2008_07_31t124523_450x335_us_markets_stocks.jpg?x=130&y=96&q=85&sig=2I4AC0InyG0ahFH7Vgt8Zw--" align="left" height="96" width="130" alt="Trading specialists work on the floor at the New York Stock Exchange, July 16, 2008. (Chip East/Reuters)" border="0" /></a>Reuters - Stocks fell on Thursday, led by Exxon Mobil after its earnings fell short of Wall Street's expectations and as disappointing economic data revived fears of a U.S. recession.</p><br clear="all"/> <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/nm/20080731/bs_nm/markets_stocks_dc"><img src="http://d.yimg.com/us.yimg.com/p/nm/20080801/2008_07_31t124523_450x335_us_markets_stocks.jpg?x=130&y=96&q=85&sig=2I4AC0InyG0ahFH7Vgt8Zw--" align="left" height="96" width="130" alt="photo" title="Trading specialists work on the floor at the New York Stock Exchange, July 16, 2008. (Chip East/Reuters)" border="0"/></a></p><br clear="all"/> (Reuters) http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080731/ap_on_bi_ge/earns_cvs_caremark ap/20080731/earns_cvs_caremark AP Thu, 31 Jul 2008 13:59:44 GMT AP - Drug store and pharmacy operator CVS Caremark said Thursday its second-quarter profit grew 7 percent as sales at its retail drug stores rose. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ap/20080731/ap_on_bi_ge/earns_aetna ap/20080731/earns_aetna AP Thu, 31 Jul 2008 10:57:50 GMT AP - Health insurer Aetna says its second-quarter profit rose 6.4 percent on membership growth and a hike in premium rates. http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/afp/20080730/bs_afp/germanypharmachemicalcompanyearningsbayer afp/20080730/germanypharmachemicalcompanyearningsbayer AFP Wed, 30 Jul 2008 09:38:03 GMT <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/afp/20080730/bs_afp/germanypharmachemicalcompanyearningsbayer"><img src="http://d.yimg.com/us.yimg.com/p/ap/20080730/capt.6bf2af629a4344999cc200637fcaf272.earns_bayer_nybz128.jpg?x=99&y=130&q=85&sig=IxEHbq7zPzamTfRVFkVppw--" align="left" height="130" width="99" alt="In this Aug. 15, 2007 file photo, flags with the company's logo flutter in front of the pharmaceutical plant of the Bayer company in Bitterfeld, eastern Germany. Chemical and pharmaceutical maker Bayer AG said Wednesday, july 30, 2008, its second-quarter profit fell 13 percent from a year-ago period boosted by one-time gains, but the company raised its sales outlook for this year. (AP Photo/Eckehard Schulz)" border="0" /></a>AFP - The German pharmaceutical and chemicals group Bayer posted a 13-percent drop in second-quarter net profit on Wednesday but said it reflected a one-off item and that the business itself had grown.</p><br clear="all"/> <p><a href="http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/afp/20080730/bs_afp/germanypharmachemicalcompanyearningsbayer"><img src="http://d.yimg.com/us.yimg.com/p/ap/20080730/capt.6bf2af629a4344999cc200637fcaf272.earns_bayer_nybz128.jpg?x=99&y=130&q=85&sig=IxEHbq7zPzamTfRVFkVppw--" align="left" height="130" width="99" alt="photo" title="In this Aug. 15, 2007 file photo, flags with the company's logo flutter in front of the pharmaceutical plant of the Bayer company in Bitterfeld, eastern Germany. Chemical and pharmaceutical maker Bayer AG said Wednesday, july 30, 2008, its second-quarter profit fell 13 percent from a year-ago period boosted by one-time gains, but the company raised its sales outlook for this year. (AP Photo/Eckehard Schulz)" border="0"/></a></p><br clear="all"/> (AFP) http://us.rd.yahoo.com/dailynews/rss/healthcare/*http://news.yahoo.com/s/ibd/20080729/bs_ibd_ibd/20080729general ibd/20080729/20080729general Investor's Business Daily Tue, 29 Jul 2008 22:55:13 GMT Investor's Business Daily - The biotech sector has been a lively one lately, thanks to events in the laboratory and the boardroom.